Lower Transfusion Threshold Safe For Most Sepsis Patients

Anders Perner, MD, PhD Overlæge / Senior staff specialist Professor / Professor in Intensive Care Dept of Intensive Care Rigshospitalet Copenhagen DenmarkMedicalResearch.com Interview with:
Anders Perner, MD, PhD
Overlæge / Senior staff specialist
Professor / Professor in Intensive Care
Dept of Intensive Care
Rigshospitalet Copenhagen Denmark

Medical Research: What are the main findings of the study?

Dr. Perner: In the large international randomised trial, we showed similar outcomes in patients with septic shock with anemia transfused at a lower vs. a higher hemoglobin threshold. The lower threshold group received 50 % fewer transfusions and one-third of these patients were never transfused in ICU.

Medical Research: What was most surprising about the results?

Dr. Perner: The results were remarkably clear.

Medical Research: What should clinicians and patients take away from your report?

Dr. Perner: Clinicians treating patients with septic shock can safely wait and transfuse at a hemoglobin level at 7 g/dl

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Perner: For the vast majority of patients 7 g/dl should be the transfusion threshold, but we need more data in those with acute coronary syndrome or severe bleeding
Citation:

 

Lars B. Holst, M.D., Nicolai Haase, M.D., Ph.D., Jørn Wetterslev, M.D., Ph.D., Jan Wernerman, M.D., Ph.D., Anne B. Guttormsen, M.D., Ph.D., Sari Karlsson, M.D., Ph.D., Pär I. Johansson, M.D., Ph.D., Anders Åneman, M.D., Ph.D., Marianne L. Vang, M.D., Robert Winding, M.D., Lars Nebrich, M.D., Helle L. Nibro, M.D., Ph.D., Bodil S. Rasmussen, M.D., Ph.D., Johnny R.M. Lauridsen, M.D., Jane S. Nielsen, M.D., Anders Oldner, M.D., Ph.D., Ville Pettilä, M.D., Ph.D., Maria B. Cronhjort, M.D., Lasse H. Andersen, M.D., Ulf G. Pedersen, M.D., Nanna Reiter, M.D., Jørgen Wiis, M.D., Jonathan O. White, M.D., Lene Russell, M.D., Klaus J. Thornberg, M.D., Peter B. Hjortrup, M.D., Rasmus G. Müller, M.D., Morten H. Møller, M.D., Ph.D., Morten Steensen, M.D., Inga Tjäder, M.D., Ph.D., Kristina Kilsand, R.N., Suzanne Odeberg-Wernerman, M.D., Ph.D., Brit Sjøbø, R.N., Helle Bundgaard, M.D., Ph.D., Maria A. Thyø, M.D., David Lodahl, M.D., Rikke Mærkedahl, M.D., Carsten Albeck, M.D., Dorte Illum, M.D., Mary Kruse, M.D., Per Winkel, M.D., D.M.Sci., and Anders Perner, M.D., Ph.D. for the TRISS Trial Group and the Scandinavian Critical Care Trials Group

N Engl J Med 2014; 371:1381-1391
October 9, 2014DOI: 10.1056/NEJMoa1406617

 

No Comments

Sorry, the comment form is closed at this time.